Table 1 Baseline characteristics of patients in nintedanib prospective study

Age (years)

71 [57–80]

69 [57–77]

73 [64–80]

0.536

Male

14 (88%)

8 (88%)

6 (86%)

0.849

Weight (kg)

61.0 [43.3–73.9]

68.7 [43.3–73.9]

59.6 [44.3–61.5]

0.055

Body mass index

24.2 [15.1–26.9]

25.1 [15.1–26.9]

22.0 [19.0–26.7]

0.210

 Never / Former / Current smoker

1 / 15 / 0

0 / 9 / 0

0 / 7 / 0

–

Time since the diagnosis of IPF (years)

4 [0–9]

2 [0–9]

4 [1–8]

0.408

Long-term oxygen treatment

9 (56%)

–

–

–

mMRC dyspnea scale

2 [0–3]

3 [0–3]

1 [0–2]

0.114

GAP score

4 [2–8]

5 [2–8]

4 [3–5]

0.174

SpO₂ on room air at rest (%)

96 [94–99]

95 [94–97]

97 [94–99]

0.234

PaO₂ on room air at rest (mmHg)

83 [59–122]

75 [59–94]

88 [81–122]

0.054

PASP measured by TTE at baseline (mmHg)

34.0 [21.0–59.0]

33.0 [21.0–59.0]

35.0 [27.6–55.3]

1.000

 FVC (mL)

1.930 [1.060–3030]

2.140 [1.060–3.030]

1.840 [1.540–2.690]

0.408

 FVC (% predicted)

62 [28–88]

66 [28–88]

57 [51–79]

0.758

 FEV₁ (mL)

1.700 [1.030–2.470]

1.990 [1.030–2.407]

1.560 [1.330–2.270]

0.536

 FEV₁ (% predicted)

68 [34–91]

67 [34–91]

76 [50–81]

0.758

 DL_CO (mL/min/mmHg)

10.2 [5.1–18.6]

8.3 [5.1–13.6]

10.7 [8.1–18.6]

0.209

 DL_CO (% predicted)

70 [30–91]

49 [30–76]

70 [48–91]

0.017

 BNP

31.6 [7.6–1.313]

28.4 [7.6–1.313]

27.2 [10.0–53.9]

0.837

 Pulmonary emphysema

6 (38%)

5 (56%)

1 (14%)

0.121

 Hypertension

6 (38%)

3 (33%)

3 (43%)

0.696

 Chronic heart failure

0 (0%)

0 (0%)

0 (0%)

–